

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).

I hereby appoint:

Practitioners associated with the Customer Number: 25885

OR

Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

| Name | Registration Number | Name | Registration Number |
|------|---------------------|------|---------------------|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:

The address associated with Customer Number: 25885

OR

| | | | |
|--|--|-------|-----|
| <input type="checkbox"/> Firm or Individual Name | | | |
| Address | | | |
| City | | State | Zip |
| Country | | | |
| Telephone | | Email | |


Assignee Name and Address:

Elanco Animal Health Ireland Limited
Finisklin Industrial Estate
Sligo IRELAND

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

| | | |
|-----------|---|------------------------------|
| Signature |  | Date <u>1 September 2011</u> |
| Name | Douglas K. Norman | Telephone 317-276-2958 |
| Title | Vice President-General Patent Counsel | |

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.


Delegation of Authority Concerning Certain Patent Matters

On behalf of Elanco Animal Health Ireland Limited, a private limited liability company incorporated in Ireland, with a principal place of business at Finisklin Industrial Estate, Sligo, Ireland, a wholly-owned subsidiary of Eli Lilly and Company, an Indiana corporation with a principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, I delegate to Douglas K. Norman, Vice President and General Patent Counsel of Eli Lilly and Company, and Amy E. Hamilton, Vice President and Deputy General Patent Counsel of Eli Lilly and Company:

Authority to approve and execute for and on behalf of Elanco Animal Health Ireland Limited, documents in connection with patent matters relating to:

- (i) the institution, prosecution, and completion of proceedings directed towards the issuance of patents;
- (ii) the amendment, restriction, renewal, reissue, revival, maintenance, restoration, cancellation, extension, and abandonment of patents and of applications for patents;
- (iii) the institution, prosecution, and termination of proceedings of interference, opposition, revocation, and nullification, including the filing of preliminary statements, concessions of priority, disclaimers, abandonments of the contents, and abandonments of the invention;
- (iv) the settlement of patent proceedings of interference, opposition, revocation, and nullification, subject to prior approval by the Senior Vice President and General Counsel of Eli Lilly and Company;
- (v) the filing of statutory disclaimers;
- (vi) the institution, prosecution, and termination of appellate proceedings; and
- (vii) the granting and the revocation of powers of attorney in connection with any of the foregoing.

Dated: SEPTEMBER 1, 2011



Thomas W. Grein
Senior Vice President-Finance and Treasurer
Elanco Animal Health Ireland Limited

